Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ABBV-706 vs standard chemotherapy in relapsed/refractory small cell lung cancer
CTR20263153Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of turmetabart adizutecan in small cell lung cancer (SCLC), sponsored by AbbVie Inc.. Started Aug 2026; status: active.
02
Drugs
turmetabart adizutecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20263153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263153.